



**fisher clinical**  
**services**

by Thermo Fisher Scientific

# CLPS LABEL PROOF



**Label ID#:** LIL10964CS1

**Label Designed By:** Phil Pesapane

**Label Revised By:** Phil Pesapane

**Template ID#:** 5250.1750.DP+.1250cp.2250bk1.1875bk2

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**

**J2N-MC-JZNX**  
AR - Argentina / Español..... 3 CA - Canada / Français ..... 11  
AU - Australia/English..... 4 CZ - Česka republika /  
AT - Österreich / Deutsch ..... 5 čestina ..... 12  
BE - Belgique / Nederlands ..... 6 DK - Danmark/Dansk..... 13  
BE - Belgique / Française / Français..... 14  
BE - Belgien / Deutsch ..... 8 DE - Deutschland / Deutsch ..... 15  
BR - Brasil / Português ..... 9 GR - Ελλάδα/Ελληνικά ..... 16  
CA - Canada / English ..... 10 HU - Magyarország/magyar ..... 17  
LIL10964 CT 06901, USA, +1 855 569 6305  
Loxo Oncology, Inc., 281 Tresser Boulevard, Stamford,

**Label ID #: LIL10964PN1**

**Label Description: Cover Panel - Table of Contents (7 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***

IN - India / English .....	18
SK - Slovenská republika /	19
slovenčina .....	27
IL - ישראל / English .....	20
IL - ישראל/לראש .....	28
KR - 한국/한국어 .....	21
ES - España/Español .....	29
IT - Italia / Italiano .....	21
JP - 日本/日本語 .....	22
TW - 台灣 / 中文 .....	30
MX - México / Español .....	23
TW - Taiwan / English .....	31
NL - Nederland /	32
TR - Türkiye/Türkeç .....	32
GB - United Kingdom /	24
Nederlands .....	32
PL - Polska / Polski .....	25
English .....	33
RO - România / Română .....	26
US - United States of America /	26
English .....	34

**Label ID #: LIL10964PN2**

**Label Description: Inside Cover Panel - Table of Contents (Cont.) (7 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**



by Thermo Fisher Scientific

# LABEL PROOF

(I) Lote: \_\_\_\_\_  
 (II) Fecha de caducidad: \_\_\_\_\_  
 (III) Número de envases: \_\_\_\_\_  
 (IV) Número de confirmación: \_\_\_\_\_  
 (V) Fecha de fabricación: \_\_\_\_\_  
 (VI) Número de paciente: \_\_\_\_\_  
 Investigador: \_\_\_\_\_  
 Vista: \_\_\_\_\_  
 50 mg LY3527727 (LOXO-305) piribrutinib.  
 Cantidad de comprimidos: 51 por frasco.  
 Solamente para uso por vía oral. Tomar según las  
 indicaciones del investigador. Tragar los comprimidos  
 enteros. No triturar, romper ni mastigar. Almacenar a  
 temperatura ambiente (de 10°C a 30°C). No destruir.  
 Devolver los envases y los medicamentos no usados al  
 investigador. Para uso exclusivo en ensayos clínicos.  
 © Mantener fuera del alcance de los niños.

AR

**Label ID #: LIL10964PN3**

**Label Description: Argentina (Spanish) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***



by Thermo Fisher Scientific

# LABEL PROOF

(i) Lot:  
(ii) Expiry Date:  
(iii) Package Number:  
(iv) Confirmation Number:  
(v) Manufacture Date:  
Investigator:  
50 mg LY3527727 (LOXO-305) pirobutinib.  
Tablet count: 31 per bottle. For oral use only.  
Take as directed by investigator. Swallow tablets whole.  
Do not crush, break or chew. Store at room temperature  
(10°C - 30°C; 50°F - 86°F). Do not destroy. Return  
packaging and unused medication to the investigator.  
For clinical trial use only. Keep out of reach of children.  
Eli Lilly Australia Pty. Limited Level 9  
60 Margaret Street Sydney NSW 2000 AUSTRALIA  
+ 61 2 9325 4444

**Label ID #:** LIL10964PN4

**Label Description:** Australia (English) (5 pt.)

**Protocol #:** J2N-MC-JZNX

**Label Designed By:** Pesapane, Phil

**Label Updated By:** Pesapane, Phil

**Template ID #:** TCN12501

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ *SIGNATURE ON FILE*

(I) Ch.-B.:  
(II) Verwendbar bis:  
(III) Paket-Nr.:  
(IV) Bestätigungs-Nr.:  
(V) Herstellungsdatum:  
Pflanzl-Nr.:  
50 mg LY352727 (LOXO-305) Probrunstab.  
Anzahl Tabletten: 31 je Flasche. Zum Einnehmen.  
Nach Anweisung des Pflanzlers einnehmen, nicht öffnen.  
Tabletten unzerkaut einnehmen. Bei Raumtemperatur  
lagern (10°C - 30°C). Nicht vernichten. Verpackung und  
unverbrauchtes Arzneimittel dem Pflanzler zurückgeben.  
Zur klinischen Prüfung bestimmt. Arzneimittel für  
Ⓢ Kinder unzugänglich aufbewahren.

AT

**Label ID #: LIL10964PN5**

**Label Description: Austria (German) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**

(I) Lot:  
(II) Vervaldatum:  
(III) Verpakkingnummer:  
(IV) Bepalingsnummer:  
(V) Productiedatum:  
(VI) Palletnummer:  
Onderzoeker:  
50 mg LY327727 (LOXO-305) LY327727.  
Aantal tabletten: 31 per fles. Uitsluitend voor  
oraal gebruik. Innemen zoals voorgeschreven door  
de onderzoeker. Tabletten moeten in hun geheel  
worden ingenomen. Niet vermalen, breken of kauwen.  
Bewaren bij kamertemperatuur (10°C – 30°C).  
Niet vernietigen. Verpakking en ongebruikte medicatie  
terugbrengen naar de onderzoeker.  
Uitsluitend bestemd voor klinisch onderzoek.  
Buiten het bereik van kinderen houden. ⑥

**Label ID #: LIL10964PN6**

**Label Description: Belgium (Dutch) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***





(I) Ch.-B.:  
(II) Verwendbar bis:  
(III) Paket-Nr.:  
(IV) Bestätigungs-Nr.:  
(V) Herstellungsdatum:  
Patent-Nr.:  
Präparat:  
50 mg LY352727 (LOXO-305) Pirobutinib.  
Anzahl Tabletten: 01 je Flasche. Zum Einnehmen.  
Nach Anweisung des Präparates einnehmen, nicht öffnen.  
Tabletten unzerkaut einnehmen, nicht öffnen.  
zerdrücken oder zerkauen. Bei Raumtemperatur  
lagern (10°C - 30°C). Nicht vernichten; Verpackung und  
unverbrauchtes Arzneimittel dem Präparat zurückgeben.  
Zur klinischen Prüfung bestimmt. Arzneimittel für  
Kinder unzugänglich aufbewahren. ③

**Label ID #: LIL10964PN8**

**Label Description: Belgium (German) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**



by Thermo Fisher Scientific

# LABEL PROOF

(I) Lote:  
 (II) Data de validade:  
 (III) Número da embalagem:  
 (IV) Número da confirmação:  
 (V) Data de fabricação:  
 Número do paciente:  
 Investigador:  
 50 mg LY327727 (LOXO-305) LY327727.  
 Quantidade de comprimidos: 31 por frasco.  
 Apenas para uso oral. Tomar de acordo com as  
 instruções das pílulas do investigador. Engolir os  
 comprimidos inteiros. Não esmagar nem quebrar  
 nem mastigar. Armazenar à temperatura ambiente  
 (10°C - 30°C). Não destruir. Devolver a embalagem e  
 os medicamentos não utilizados ao investigador.  
 Para uso exclusivo em Pesquisa Clínica.  
 ③ Manter fora do alcance das crianças.

BR

**Label ID #: LIL10964PN9**

**Label Description: Brazil (Portuguese) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***



by Thermo Fisher Scientific

# LABEL PROOF

(i) Lot: CA  
 (ii) Expiry Date:  
 (iii) Package Number:  
 (iv) Confirmation Number:  
 (v) Manufacture Date:  
 (vi) Patent number:  
 Investigator:  
 50 mg LY3527727 (LOXO-305) pitobutmb.  
 Tablet count: 31 per bottle. For oral use only.  
 Take as directed by investigator. Swallow tablets whole.  
 Do not crush, break or chew. Store at room temperature  
 (10°C - 30°C; 50°F - 86°F). Do not destroy. Return  
 packaging and unused medication to the investigator.  
 Investigational Drug: To Be Used By Qualified  
 Investigator Only. Keep out of reach of children.  
 Eli Lilly Canada Inc., Toronto, Canada MSX 181

**Label ID #:** LIL10964PN10

**Label Description:** Canada (English) (5 pt.)

**Protocol #:** J2N-MC-JZNX

**Label Designed By:** Pesapane, Phil

**Label Updated By:** Pesapane, Phil

**Template ID #:** TCN12501

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ *SIGNATURE ON FILE*

(I) Lot : CA  
(II) Date de péremption :  
(III) Numéro de paquet :  
(IV) Numéro de confirmation :  
(V) Date de fabrication :  
Chercheur :  
50 mg LY3527727 (LOXO-305) pirobutinb  
Nombre de comprimés : 31 par flacon, Par voie  
orale uniquement. Prendre le médicament selon  
les instructions du chercheur. Avaler les comprimés  
entiers. Ne pas écraser, briser ou mâcher. Conserver à  
température ambiante (10 °C à 30 °C; 50 °F à 86 °F).  
Ne pas détruire. Retourner les emballages et le  
médicament non utilisé au chercheur. Médicament de  
recherche : réservé à l'usage de chercheurs  
compétents. Garder hors de la portée des enfants.  
© Eli Lilly Canada Inc., Toronto, Canada M5X 1B1

**Label ID #:** LIL10964PN11

**Label Description:** Canada (French) (5 pt.)

**Protocol #:** J2N-MC-JZNX

**Label Designed By:** Pesapane, Phil

**Label Updated By:** Pesapane, Phil

**Template ID #:** TCN12501

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**

(I) Č. šarže: \_\_\_\_\_  
(II) Použitelné do: \_\_\_\_\_  
(III) Číslo balení: \_\_\_\_\_  
(IV) Ověřovací číslo: \_\_\_\_\_  
(V) Datum výroby: \_\_\_\_\_  
Číslo pacienta : \_\_\_\_\_  
Zkoušející lékař: \_\_\_\_\_  
50 mg LY352727 (LOXO-305) LY352727.  
Pouze tablet 31 v jedné ianvi. Pouze pro  
perorální podání. Užívejte podle pokynů zkoušejícího.  
Poukřejte tablety vešiku. Tablety neďte, nepřesamuje  
ani nezvykřejte. Uchovávejte při pokojové teplotě  
(10 °C - 30 °C). Nevhazujte. Prázdná balení a  
nevyužitvané léky vrátte zkoušejícímu. Pouze pro užití  
klinického hodnocení. Uchovávejte mimo dosah dětí. ®

**Label ID #: LIL10964PN12**

**Label Description: Czech Republic (Czech) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**

(I) Lot: \_\_\_\_\_  
(II) Udløbsdato: \_\_\_\_\_  
(III) Pakningsnummer: \_\_\_\_\_  
(IV) Bækræfttælsnummer: \_\_\_\_\_  
(V) Fremstillingsdato: \_\_\_\_\_  
Patientnummer: \_\_\_\_\_  
Investigator: \_\_\_\_\_  
50 mg LY352727 (LOXO-305) LY352727.  
Anat. tabletter: 31 pr. haske. Kun til oral brug.  
Skal tages efter forsøgstægens anvisninger.  
Tabletterne skal sluges hele. Tabletterne må ikke  
knuses, brækkes over eller tygges. Opbevares ved  
stuetemperatur (10 °C - 30 °C; 50°F - 86°F).  
Må ikke destrueres. Røntgen er endeligt og ubrugt  
lægemiddel til forsøgsløsning. Opbevares uliggeligt  
for børn. Kun til brug ved klinisk forsøg.

**Label ID #: LIL10964PN13**

**Label Description: Denmark (Danish) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***



(I) Ch.-B.:  
(II) Verwendbar bis:  
(III) Paket-Nr.:  
(IV) Bestätigungs-Nr.:  
(V) Herstellungsdatum:  
Patienten-Nr.:  
Präparat:  
50 mg L<sub>3527727</sub> (LOXO-305) Probrinib.  
Anzahl Tabletten: 31 je Flasche. Zum Einnehmen.  
Nach Anweisung des Präparates einnehmen.  
Tabletten unzerkaut einnehmen, nicht öffnen.  
Zerdrücken oder zerkauen. Bei Raumtemperatur lagern  
(10°C - 30°C). Nicht vernichten. Verpackung und  
unverbrauchtetes Arzneimittel dem Praktiker zurückgeben.  
Zur klinischen Prüfung bestimmt. Arzneimittel für Kinder  
unzugänglich aufbewahren. CRO: OVIA RDS GmbH  
Unterschweinstiege 2-14, 60549 Frankfurt am Main,  
DEUTSCHLAND +49 (0) 69 6604 0

**Label ID #: LIL10964PN15**

**Label Description: Germany (German) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***



(I) Γραφίδα:  
 (II) Ημερομηνία αήληψ:  
 (III) Αριθμός συσκευασίας:  
 (IV) Αριθμός επιβλεπόμενων:  
 (V) Ημερομηνία παραγωγής:  
 Αριθμός σέρβους:  
 50 mg LY362127 (LOXO-305) LY362127.  
 Αριθμός δισκίων: 31 ανά φιάλη. Μόνο για από του στόματος χρήση. Να αμφοτέρωτα συμπεριληφθεί με τις οδηγίες του ερευνητή, καταστήστε τα δισκία οκκλήρα. Μην τα θραύετε, μην τα στείρετε και μην τα μασάτε. Μην το καταστρέψετε. Επιστρέψτε τη συσκευασία και το φιαλίδιο σε θερμοκρασία δωματίου (10°C - 30°C). Μην χρησιμοποιείτε φάρμακο στον ερευνητή. Μόνο για χρήση σε κλινική μελέτη. Να διατηρηθεί σε μέρος που δεν φέδον και δεν βρέθουν τα παιδιά.

**Label ID #: LIL10964PN16**

**Label Description: Greece (Greek) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**

(I) Gy.sz.:  
(II) Lejáratii idő:  
(III) Csomagszám:  
(IV) Ellenőrző szám:  
(V) Gyártás dátuma:  
Bejegyzési:  
50 mg LY327727 (LOXO-305) piributimib.  
Tabletták száma: 31 lvegenként, kizárólag szájon  
át történő alkalmazásra. A vizsgálólvezerő utasításai  
szint kell bevenni. A tablettát egészen nyelje le.  
Nem szabad eszezuini, szétörni vagy szétörni.  
Szobahőmérsékleten (10°C - 30°C) tárolandó. Típus  
megemmisíteni. A csomagolást és a fel nem használt  
gyógyszert a vizsgálólvezerőhöz kell visszaküldeni.  
Csak klinikai vizsgálati céljára használható. A gyógyszer  
® gyemnekéti elzárva tartandó!

HU

**Label ID #: LIL10964PN17**

**Label Description: Hungary (Hungarian) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**


**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**



by Thermo Fisher Scientific

# LABEL PROOF



(I) Lot: IN  
 (II) Expiry Date:  
 (III) Package Number:  
 (IV) Confirmation Number:  
 (V) Manufacture Date:  
 (VI) Patent number:  
 Investigator:  
 50 mg LY3527727 (LOXO-305) pirarubicin.  
 Tablet count: 31 per bottle. For oral use only.  
 Take as directed by investigator. Swallow tablets whole.  
 Do not crush, break or chew. Store at room temperature  
 (19°C - 30°C). Do not destroy. Return packaging and  
 unused medication to the investigator. Keep out of  
 reach of children. For Clinical Studies Only.  
 Manufacturer: Lilly del Caribe, Inc. 12.6 Km 65th  
 Infantry Road (PR01) Carolina, Puerto Rico (PR)  
 00985 USA

**Label ID #:** LIL10964PN18

**Label Description:** India (English) (5 pt.)

**Protocol #:** J2N-MC-JZNX

**Label Designed By:** Pesapane, Phil

**Label Updated By:** Pesapane, Phil

**Template ID #:** TCN12501

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***





(I) Lotto:  
(II) Data di scadenza:  
(III) Numero della confezione:  
(IV) Numero di confezione:  
(V) Data di produzione:  
Numero del paziente:  
Spermatore:  
50 mg LY327727 (LOXO-305) piributimib.  
Quantità delle compresse: 31 per fiascone. Solo per  
uso orale. Assumere secondo le indicazioni fornite dal  
medico spermatore. Deglutire le compresse intere.  
Non schiacciare, rompere o masticare. Conservare a  
temperatura ambiente (10°C - 30°C). Non distruggere.  
Restituire le confezioni e il farmaco non utilizzato al  
medico spermatore. Solo per spermiazione al  
clinica. Tenere fuori dalla portata dei bambini.  
© Non per la vendita né per la rivendita.

**Label ID #: LIL10964PN21**

**Label Description: Italy (Italian) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**







(I) Lot:  
 (II) Vervaldatum:  
 (III) Verpakingsnummer:  
 (IV) Bepastingsnummer:  
 (V) Productiedatum:  
 (VI) Palletnummer:  
 Onderzoeker:  
 50 mg LY327727 (LOXO-305) LY327727.  
 Aantial tabletten: 31 per fles. Uitsluitend voor oraal  
 gebruik. Inname zoals voorgeschreven door de  
 onderzoeker. Tabletten moeten in hun geheel  
 worden ingenomen. Niet vermalen, breken of kauwen.  
 Bewaren bij kamertemperatuur (10°C – 30°C). Niet  
 vernietigen. Verpakking en ongebruikte medicatie  
 terugbrengen naar de onderzoeker. Uitsluitend  
 bestemd voor klinisch onderzoek. Buiten het  
 bereik en zicht van kinderen houden.

**Label ID #: LIL10964PN24**

**Label Description: Netherlands (Netherlands) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**

(I) Nr serii:  
(II) Termin ważności:  
(III) Numer opakowania:  
(IV) Numer partii:  
(V) Data produkcji:  
Numer pacjenta:  
Badacz:  
50 mg LY352727 (LOXO-305) LY352727.  
Liczba tabletek: 31 na butelkę. Wyłącznie do  
podania doustnego. Przyjmować zgodnie z  
zaleceniami badacza. Tabletki połkać w całości,  
nie kruszyć, nie łamać ani nie żuć. Przechowywać w  
temperaturze pokojowej (10°C – 30°C). Nie niszczyć.  
Opakowanie i niezutyty lek zwrócić badaczowi.  
Wyłącznie do użytku w badaniu klinicznym. Lek  
© przechowywać w miejscu niedostępnym dla dzieci.

PL

**Label ID #: LIL10964PN25**

**Label Description: Poland (Polish) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**



(I) Sarža:  
(II) Dátum expirácie:  
(III) Číslo balenia:  
(IV) Číslo potvrdenia:  
(V) Dátum výroby:  
Číslo pacienta: \_\_\_\_\_  
Skušajúci lekár: \_\_\_\_\_  
50 mg LY352727 (LOXO-305) LY352727.  
Počet tabliet: 31 v jednej fľaši. Len na perorálne  
použitie. Používajte podľa pokynov skúšajúceho lekára.  
Tabliety prehltajte celé. Neďte, nehlajte ani nežujte.  
Uchovávajte pri izbovej teplote (10°C – 30°C).  
Neukidovať. Obal spolu s nepoužitým liekom vráťte  
skúšajúceho lekárovi. Uchovávajte mimo dosahu a  
© dohľadu detí. VZORKA NA KLINICKE SKÚŠANIE.

**Label ID #: LIL10964PN27**

**Label Description: Slovakia (Slovak) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***

(I) 코드: KR  
 (II) 사용자(의사)기함:  
 (III) 포장 번호:  
 (IV) 확인 번호:  
 (V) 제조일:  
 환자 번호:  
 연구자: \_\_\_\_\_  
 50 mg LY352727 (LOXO-305) LY352727.  
 정제 개수: 31 병입. 경구 복용에 적합.  
 연구자의 지시대로 복용하십시오. 정제를  
 으개거나 쪼개거나 씹지 말고, 물처럼  
 삼키십시오. 복용 (10°C - 30°C; 50°F - 86°F)  
 에서 보관하십시오. 파기하지 마십시오. 포장과  
 미사용 약물은 연구자에게 반납하십시오.  
 임상 시험용. 어린이 손이 닿지 않는  
 곳에 두십시오. 한국 릴리

**Label ID #: LIL10964PN28.1**

**Label Description: South Korea (Korean) (6 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Chahin, Ana**

**Label Updated By: Chahin, Ana**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**

(I) Lote:  
(II) CAD:  
(III) Número de envase:  
(IV) Número de confirmación:  
(V) Fecha de fabricación:  
Número de paciente:  
Investigador:  
50 mg LY352727 (LOXO-305) LY352727.  
Número de comprimidos: 31 por frasco.  
Para uso exclusivo por vía oral. Tomar según las indicaciones del investigador. Tragar los comprimidos enteros. No triturar, romper ni mastigar. Conservar a temperatura ambiente (entre 10°C y 30°C). No destruir. Devolver los envases y medicamentos no usados al investigador. Para uso exclusivo en ensayos clínicos.  
© Mantener fuera del alcance de los niños.

**Label ID #: LIL10964PN29**

**Label Description: Spain (Spanish) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***







(I) Lot: TR  
(II) Son Kullanma Tarihi:  
(III) Paket Numarası:  
(IV) Kontrollasyon Numarası:  
(V) Üretim Tarihi:  
Hasta numarası:  
Araştırmaç: \_\_\_\_\_  
50 mg LY352727 (LOXO-305) LY352727.  
Tablet sayısı: 31 her bir şişe için. Yalnız oral  
kullanım içindir. Araştırmanın belirliği şekilde alınır.  
Tabletleri bütün olarak yutunuz. Ezmeyin, kırmayın ya  
dağıtmeyiniz. Oda sıcaklığında (10°C – 30°C)  
saklayınız. İmha etmeyiniz. Ambalajları ve  
kullanılmamış ilaçları araştırmaçaya lade ediniz.  
Çocukların erişemeyeceği bir yerde saklayınız.  
Yalnızca klinik araştırma kullanımını içindir.

**Label ID #: LIL10964PN32**

**Label Description: Turkey (Turkish) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ **SIGNATURE ON FILE**



by Thermo Fisher Scientific

# LABEL PROOF

(I) Lot: GB  
 (II) Expiry Date:  
 (III) Package Number:  
 (IV) Confirmation Number:  
 (V) Manufacture Date:  
 Patient number:  
 Investigator: \_\_\_\_\_  
 50 mg LY352727 (LOXO-305) pirobutinib.  
 Tablet count: 31 per bottle. For oral use only.  
 Take as directed by investigator. Swallow tablets whole.  
 Do not crush, break or chew. Store at room temperature  
 (10°C - 30°C; 50°F - 86°F). Do not destroy. Return  
 packaging and unused medication to the investigator.  
 © For clinical trial use only. Keep out of reach of children.

**Label ID #: LIL10964PN33**

**Label Description: United Kingdom (English) (5 pt.)**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**


**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***



by Thermo Fisher Scientific

# LABEL PROOF



(i) Lot: \_\_\_\_\_  
(ii) Expiry Date: \_\_\_\_\_  
(iii) Package Number: \_\_\_\_\_  
(iv) Confirmation Number: \_\_\_\_\_  
(v) Manufacture Date: \_\_\_\_\_  
Patent number: \_\_\_\_\_  
Investigator: \_\_\_\_\_  
50 mg LY3527727 (LOXO-305) pitobrutinib.  
Tablet count: 31 per bottle. For oral use only.  
Take as directed by investigator. Swallow tablets whole.  
Do not crush, break or chew. Store at room temperature  
(10°C - 30°C; 50°F - 86°F). Do not destroy. Return  
packaging and unused medication to the investigator.  
Keep out of reach of children. CAUTION: New  
drug - Limited by Federal (or United States) law to  
investigational use.

**Label ID #: LIL10964PN34**

**Label Description: United States of America (English) (5 pt.)**

**Protocol #: J2N-MC-JZNX**


**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***



**Label ID #: LIL10964PN35**

**Label Description: Blank**

**Protocol #: J2N-MC-JZNX**


**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_

**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***



**Label ID #: LIL10964PN36**

**Label Description: Blank**

**Protocol #: J2N-MC-JZNX**

**Label Designed By: Pesapane, Phil**

**Label Updated By: Pesapane, Phil**

**Template ID #: TCN12501**

**Client Approval:** \_\_\_\_\_


**IPI:** \_\_\_\_\_ ***SIGNATURE ON FILE***



by Thermo Fisher Scientific

# LABEL PROOF

Repeat = 5-1/2"



Label ID #: LIL10964BP1

Label Description: LIL10964 Digital Base Panel

Protocol #: J2N-MC-JZNX

Label Designed By: Pesapane, Phil

Label Updated By: Pesapane, Phil

Template ID #: TCN12501

Space Between  
Around  
0.5"

Client Approval: \_\_\_\_\_

IPI: \_\_\_\_\_ **SIGNATURE ON FILE**